Abstract
PurposeGastric cancer (GC) is the fifth leading cancer around world. And prognosis of patients with GC is still undesirable. Our study aimed to explore potential prognostic biomarkers for patients with GC.MethodsThe clinical samples were collected from the Qinghai University Affiliated Hospital, which were subjected to the whole exome sequencing (WES). The other GC-related data were obtained from The Cancer Genome Atlas (TCGA) database. Cross analyses were done to determine the candidate genes. And the final mutated genes were determined by survival analyses, univariate and multivariate Cox regression analyses. CIBERSORT and GSEA were used for immune cell infiltration analysis and functional enrichment, respectively.ResultsAfter cross analyses, 160 candidate-mutated genes were identified. And mutated ELP6 and PLIN5 were significantly independently correlated with the overall survival (OS) of patients with GC. Patients with GC with ELP6 and PLIN5 mutations had worse and better prognosis, respectively. Totally 5 types of immune cells were significantly differentially infiltrated in wild-type and mutated ELP6 and PLIN5 GC samples. In mutated ELP6 and PLIN5 GC samples, totally 7 and 11 pathways were significantly enriched, respectively.ConclusionsThe ELP6 and PLIN5 mutations were probably prognostic biomarkers for patients with GC.
Highlights
Gastric cancer (GC), as the fifth leading cancer and the fourth cause of mortality related to cancer, is a heavy health burden worldwide, leading to ∼760,000 deaths per year [1, 2]
We found that mutated ELP6 and PLIN5 were significantly related to the overall survival (OS) of patients with GC (p < 0.05)
The results suggested that ELP6 was still significantly associated with the OS of patients with GC, and taking wild-type as reference, GC samples with ELP6 mutation had a higher risk of death (HR = 15.970, 95%CI: 4.222– 60.406, p < 0.001) (Figure 1D)
Summary
Gastric cancer (GC), as the fifth leading cancer and the fourth cause of mortality related to cancer, is a heavy health burden worldwide, leading to ∼760,000 deaths per year [1, 2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
